BIO-Europe Spring 2009 Presenter and Exhibitor Profiles
Last Updated on Friday, 13 March 2009 01:34 Written by Editor Friday, 13 March 2009 01:34
MILAN, Mar 12, 2009 (BUSINESS WIRE) — BIO-Europe Spring 2009 takes place March 16-18, 2009 at the Milano Convention Centre in Milan, Italy.
Business Wire is the official news wire for BIO-Europe Spring 2009. Breaking news releases, advisories, photos, and multimedia are available at Tradeshownews.com, Business Wire’s trade show, conference, and event news resource.
Listed below are the BIO-Europe Spring 2009 exhibitor and presenter profiles.
Company: Addex Pharmaceuticals Ticker Symbol & Exchange: ADXN Media Contact: Chris Maggos Phone:41 22 884 15 11
E-mail: chris.maggos@addexpharma.com Web: www.addexpharma.com Addex Pharmaceuticals discovers and develops allosteric modulators for human health. Allosteric modulators are a different kind of orally available small molecule therapeutic agent, which we believe will offer patients better results than classical drugs. The lead product in our pipeline, ADX10059, has achieved clinical proof of concept and is in Phase IIb testing for the treatment of GERD (e.g. heartburn) and, separately, migraine headache. ADX10059 is a first-in-class mGluR5 inhibitor, a therapeutic strategy that also is being pursued for multiple indications by large pharma competitors. ADX10059 is not yet partnered but we have established drug development deals with Merck & Co., Inc. (2 deals: schizophrenia & Parkinson's) and Ortho McNeil Pharmaceuticals, a J&J company (anxiety/schizophrenia). Roche Ventures and SR One (GlaxoSmithKline's VC investing unit) have invested in Addex. Company: Allon Therapeutics Inc. Ticker Symbol & Exchange: TSX:NPC Media Contact: Aaron Keay, Director, Investor Relations Phone:
604-742-2540
E-mail: akeay@allontherapeutics.com Web: www.allontherapeuticsc.com Allon Therapeutics Inc. is a clinical-stage biotechnology company developing treatments for major neurodegenerative conditions. Allon's drug AL-108 (davunetide) has demonstrated human efficacy in amnestic mild cognitive impairment, a precursor to Alzheimer's disease. Allon has Phase II human efficacy programs pursuing large underserved markets: Alzheimer's disease, frontotemporal dementia, and schizophrenia-related cognitive impairment. Company: Almac Group Stand: 10 Media Contact: Carl Whyte (Stakeholder Communicati) Phone:
44(0)28 3833 2200
E-mail: info@almacgroup.com Web: www.almacgroup.com Almac's integrated development services extend from research to commercialisation of product. Our extensive facilities in Europe and North America offer the following: -Route design & synthesis of APIs (including potent, peptide and chiral compounds); -Synthesis and formulation of labelled compounds (pre-clinical and clinical); -Formulation development of tablets and capsules; -Gene expression profiling & bioinformatics; -Manufacturing/blinding, packaging, randomised labelling and distribution of clinical supplies; -Clinical trial technology solutions based on IVRS/Web/EDC; -Commercial scale manufacture and distribution; -Comprehensive analytical service; -EU import testing and QP release for clinical and commercial product. Company: AmberCRO, ltd Media Contact: Julija Gabrusenoka Phone: 37129340168 E-mail: gabrusenokaj@amber-cro.com Web: www.amber-cro.com AmberCRO is a private CRO company providing Contract Research Organization services in Baltic Countries. Started from feasibility to Close out Visits including additional services: Independent Audit services Study Design, Protocol Development, Case report Form, Design and Preparation. Selection process. Site and Investigator selection. Regulatory Consultation. Preparation and submission of Regulatory documents (clinical trial application/ Notification). Organize Investigator meeting, qualify and train Investigators ICH/GCP training Site Management and Monitoring Based on SOP's and study specific procedures. AmberCRO is providing services for reasonable price with high quality. AmberCRO has established its own EDC system with High data security, elastic database structure, easy navigation, simple data verification system, comprehensive report system. Company: FGK Clinical Research GmbH Stand: 18 Media Contact: Dr. Edgar J. Fenzl Phone:
49 - 89 - 893119-0
E-mail: edgar.fenzl@fgk-cro.de Web: www.fgk-cro.de FGK Clinical Research GmbH is a full service contract research organization offering a complete range of clinical development and consulting services to pharmaceutical, biotechnology and medical device companies. With more than 50 highly skilled and experienced people, FGK operates out of Munich on local and global projects, covering clinical studies from phases II to IV. FGK has extensive experience in all major therapeutic areas and clinical research fields, which allows it to effectively design, manage and analyze your development programs and clinical trials. Company: Hospira One 2 One Stand: 4 Ticker Symbol & Exchange: HSP Phone:
44 (0) 1926 835 554
E-mail: one2one@hospira.com Web: http://one2one.hospira.com Hospira is a global specialty pharmaceutical and medication delivery company. The company's One 2 One(R) business is a world leader in the custom development and manufacture of parenteral products packaged in vials, prefilled syringes, cartridges, flexible containers and ampules. One 2 One(R) offers development and manufacturing services at its worldwide facilities located in North America, Europe and Australia. Company: Hybrigenics Ticker Symbol & Exchange: ALHYG (NYSE-Euronext) Phone:
(33) 1 58 10 38 00
E-mail: contact@hybrigenics.com Web: www.hybrigenics.com Hybrigenics is a public bio-pharmaceutical company focusing its R&D programs on innovative targets and therapeutics against cancer. Its most advanced development program is based on inecalcitol, a vitamin D analogue, for prostate cancer in combination with reference treatments, for improved efficacy and better tolerance. Hybrigenics' research program explores the role of Ubiquitin-Specific Proteases (USPs) in the degradation of proteins involved in cancer (oncoproteins), and the use of proprietary USP inhibitors against various cancer types. Hybrigenics also commercializes expert protein interaction services dedicated to identify, validate and inhibit protein interactions for academic and industrial researchers from all life sciences. Its flagship technology is a unique ISO 9001-certified Yeast-Two Hybrid (Y2H) high throughput screening platform, backed by bioinformatic tools. Company: InNexus Biotechnology Inc. Ticker Symbol & Exchange: IXS.V: Toronto Stock Exchange Media Contact: Jeff Morhet, Chairman & CEO Phone:
480-862-7500
E-mail: jmorhet@ixsbio.com Web: www.ixsbio.com InNexus is a drug development company commercializing the next generation of monoclonal antibodies based on its DXL(TM) technology, which improves the potency of existing antibody products while opening new markets and disease applications. In a short period of time, InNexus has assembled facilities, resources, a stellar Scientific Advisory Board, staff and milestones yielding multiple pre-clinical candidates targeting cancer and other commercial opportunities. InNexus has launched into pre-clinical development its first four products, DXL625 (CD20) for non-Hodgkin's lymphoma, DXL702 (HER-2/neu) for breast cancer, DXL1218 for colorectal cancer and DXL1215 for endometriosis. InNexus has numerous products and platform opportunities for antibodies. Company: PEPperPRINT GmbH Media Contact: Dr. Volker Stadler Phone:
49-6221-424744
E-mail: info@pepperprint.com Web: www.pepperprint.com By means of laser printing, PEPperPRINT produces high density peptide and peptidomimetic arrays on conventional glass slides. For the first time, tens of thousands of individual peptides are available at moderate costs. PEPperPRINT markets customized peptide arrays on demand for proteome research (antibody profiling, epitope mapping, screening for enzyme substrates...). Additionally, on a fee-for-service basis, PEPperPRINT provides truly large scale peptide and peptidomimetic libraries for biomarker discovery and drug development. PEPperPRINT adds speed and throughput on your experiment. Company: Resverlogix Corp. Ticker Symbol & Exchange: TSX:RVX Media Contact: Theresa Kennedy Phone: 1.604.538.7072 E-mail: Theresa@Resverlogix.com Web: www.resverlogix.com Resverlogix Corp. is a leading biotechnology company engaged in the development of novel therapies for important global medical markets with significant unmet needs. The NexVas(TM) PR (plaque regression) program is the Company's primary focus which is to develop novel small molecules that enhance ApoA-I. These vital therapies address the grievous burden of atherosclerosis and other important diseases such as acute coronary syndrome, diabetes, Alzheimer's disease, Peripheral Artery Disease and other vascular disorders. Resverlogix Corp. trades on the Toronto Stock Exchange (CA:RVX: news , chart , profile ) . For further information please visit www.resverlogix.com Company: ViroStatics, srl Media Contact: Michael Stevens Phone:
1 609 213-5287
E-mail: m.stevens@virostatics.com Web: virostatics.com Dr. Franco Lori, Chief Executive Officer of Virostatics, will present a Company overview during BIO-Europe Spring 2009 at 09:30 AM on Wednesday, 18 March, 2009. Dr. Lori will update recent Company advancements in drug discovery and development in the areas of HIV/AIDS and cancer as well as the potential for the Company's proprietary biomarker assays. Dr. Lori will review how Anti-Viral Hyper-Activation Limiting Therapies (AV-HALT) represent a new family of antivirals designed to not only suppress viruses but also to preserve the immune system from chronic damage. Dr. Lori will also discuss in-licensing and partnering opportunities in HIV/AIDS and cancer.
This entry was posted on Friday, March 13th, 2009 at 1:34 am and is filed under Collaborations, Europe, Events, Industry News, Press Releases, USA and Canada.
You can follow any responses to this entry through the RSS 2.0 feed.
Responses are currently closed, but you can trackback from your own site.
Main Menu
- Home
- About Bioscreening.net
- Glossary
- Biotechnology Glossary A-I
- Biotechnology Glossary J-Q
- Biotechnology Glossary R-Z
- Bird Flu
- Cheminformatic Glossary
- Endotoxins
- Fullerenes
- Genipin
- Gossypol (Gossipol)
- Grants, Venture Capital, and Government Funding
- High-throughput screening
- Lipinski Rule-of-Five
- Mumie
- Natural Medicine
- Rule-of-Three (Ro3)
- Targeted Libraries
- Web Directory






